US drugmaker AbbVie (NYSE:ABBV) revealed late yesterday that it has reached agreement to acquire US biopharma company Pharmacyclics (Nasdaq: PCYC) and its flagship asset Imbruvica (ibrutinib), a highly effective treatment for hematologic malignancies.
The news came just as rumors of a takeover from two other companies were circulating. Already up 6.3% to $230.48 in regular trading, Pharmacyclics stock gained a further 2.9% to $237.20 in after-hours trading yesterday.
The acquisition accelerates AbbVie’s clinical and commercial presence in oncology, strengthening its already robust pipeline, and establishing its strong leadership position in hematological oncology – an attractive and rapidly growing market, now approaching $24 billion globally. The acquisition adds to AbbVie’s already comprehensive pipeline and strong growth prospects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze